Skip to main content
FDA accepts biologics application for rickets treatment
10/11/2017

Burosumab, a treatment for X-linked hypophosphatemia, a heritable form of rickets, from Ultragenyx Pharmaceutical and Kyowa Hakko Kirin International was accepted for priority review by the FDA.

Full Story: